Price: RM1.14
Target Price: RM1.48
Recommendation: BUY
· 2Q09 results were mainly within expectations. 6M09 revenue of RM135.4m came in at 47.4% of our expectations while net at RM7m was only 40.6%. The slight underperformance at the net was mainly due to forex hedging losses which amounted to RM8.6m for the 6M09 without which the numbers would have far exceeded our initial forecast.
· QoQ, revenue was flat with 2Q09 revenue down 1.3%. With capacity utilization of its 2.2b Malaysian capacity very much maxed out in the near term, the group was therefore unable to capitalize immensely from the recent surge in demand as a result of the flu pandemic. GP margins however moved up 12 basis points to 23.4% as a result of lower input prices and continuous cost containment exercises.
· YoY, revenue was up 11.8% but net was down 35.9% mainly as a result of the RM8.6m in hedging losses. Normalised, bottomline could have improved by a substantial 42% on the back of a near 12% improvement in topline performance.
· Worst had been seen. Management is confident that the worst is behind with the currency hedge likely to have run its course by the end of FY09. While there remains to have some lingering impact still for the next two quarters, the impact at the absolute is likely to be much lesser compare to the first 6 months of the year.
· Demand remains robust with new products gaining traction across the globe. As a result, management is earmarking another new expansion in Kluang with another 2.5 billion pieces (83% increase) capacity dedicated to producing synthetic medical gloves. Capital expenditure of RM15m – RM20m had been budgeted with capacity likely to come on line by the 2nd quarter 2010.
· Forecast is lowered but target price is raised to RM1.48. We are lowering our FY09 net profit by 10% taking into account a higher than expected hedging losses. We are also lowering our FY10 numbers by 7.9% as we factor in higher interest expenses which we had been conservative previously. As we introduce our FY11 numbers and roll over valuation to CY10, a new target price of RM1.48 is derived based on 8x earnings. BUY maintained.
Custom Search
Showing posts with label Adventa. Show all posts
Showing posts with label Adventa. Show all posts
Wednesday, 1 July 2009
Tuesday, 1 April 2008
KENANGA: Adventa - BUY - 31 Mar 2008
Adventa – Dividends surprise (Results Note)
Price: RM1.19
Target Price: RM1.90
Recommendation: BUY
· Commendable finals with revenue and bottomline growing by 29.6% and 24.9% respectively on the back of improved production and rising demand for surgical and dental especially. For the full year, we estimate that sales of surgical and examination gloves would have grown by 10% while dental up by at least 50%.
· Final results though commendable but is still short of our expectations. Topline of RM224.9m was at 91.5% of our full year’s forecast while bottomline of RM20.1m at 90.5%. Our more aggressive assumption on both production and the exchange rate were mainly to blame for the short-fall while some further gestation on the Uruguay operation had contributed to the slight underperformance.
· QoQ, topline was lower at 4.8% while net profit was higher by 16.2%. The lower topline for the 4Q08 was mainly attributable to a combination of less favourable product mix and the strengthening of the local unit – RM. Lower effective taxes as a result of investment allowances had helped to shore up bottomline performance for the period.
· Dividend surprise. Company has declared a final tax-exempt dividend of 4.4sen or a payout of 30% which is much higher than our forecast of a 20% payout. Balance sheet remains most healthy still after placing out 9m shares at RM1.56 recently, raising some RM14m to fund its capital expansion. Post dividend payment, net gearing remains a comfortable 36%.
· Forecast is revised lower on account of a stronger RM, higher production costs on the back of rising latex prices as well as a slightly more conservative assumption overall on our part. Our topline forecasts for FY09 and FY10 are lowered by 11.6% and 10.9% respectively while net profit for the two years have been lowered accordingly by 15.3% and 19%. As a result, our target price is also lowered to RM1.90 from RM2.48 previously, applying the same 9.5x multiple.
· Despite the lowering of our forecast and targets, we continue to rate the company a BUY given the encouraging prospects in the medical glove segment especially surgical. Strong R&D capability, product niche especially in the high-end surgical couple with a growing suite of products and solutions should set a strong platform for the company in becoming a supply chain leader in the healthcare institutions in the Asean region.
KENANGA INVESTMENT BANK BERHAD (15678-H)
Research Department
Price: RM1.19
Target Price: RM1.90
Recommendation: BUY
· Commendable finals with revenue and bottomline growing by 29.6% and 24.9% respectively on the back of improved production and rising demand for surgical and dental especially. For the full year, we estimate that sales of surgical and examination gloves would have grown by 10% while dental up by at least 50%.
· Final results though commendable but is still short of our expectations. Topline of RM224.9m was at 91.5% of our full year’s forecast while bottomline of RM20.1m at 90.5%. Our more aggressive assumption on both production and the exchange rate were mainly to blame for the short-fall while some further gestation on the Uruguay operation had contributed to the slight underperformance.
· QoQ, topline was lower at 4.8% while net profit was higher by 16.2%. The lower topline for the 4Q08 was mainly attributable to a combination of less favourable product mix and the strengthening of the local unit – RM. Lower effective taxes as a result of investment allowances had helped to shore up bottomline performance for the period.
· Dividend surprise. Company has declared a final tax-exempt dividend of 4.4sen or a payout of 30% which is much higher than our forecast of a 20% payout. Balance sheet remains most healthy still after placing out 9m shares at RM1.56 recently, raising some RM14m to fund its capital expansion. Post dividend payment, net gearing remains a comfortable 36%.
· Forecast is revised lower on account of a stronger RM, higher production costs on the back of rising latex prices as well as a slightly more conservative assumption overall on our part. Our topline forecasts for FY09 and FY10 are lowered by 11.6% and 10.9% respectively while net profit for the two years have been lowered accordingly by 15.3% and 19%. As a result, our target price is also lowered to RM1.90 from RM2.48 previously, applying the same 9.5x multiple.
· Despite the lowering of our forecast and targets, we continue to rate the company a BUY given the encouraging prospects in the medical glove segment especially surgical. Strong R&D capability, product niche especially in the high-end surgical couple with a growing suite of products and solutions should set a strong platform for the company in becoming a supply chain leader in the healthcare institutions in the Asean region.
KENANGA INVESTMENT BANK BERHAD (15678-H)
Research Department
Subscribe to:
Posts (Atom)